Skip to main content

Table 3 Topics receiving highest priority rankings for funded comparative Effectiveness Systematic Reviews in CKD

From: Setting an agenda for comparative effectiveness systematic reviews in CKD care

Topic CKD
Area
Rank* Feasibility
    Systematic reviews **Randomized controlled trials
     Pharmacologic Behavioral †Priority population
Proteinuria Progression 1 9 >100 20 0
Access to care Progression 2 1 2 2 2
Hypertension Progression 2 11 68 3 37
Screening benefits and harms Detection 3 1 0 0 0
Hypertension control Prevention 4 0 1 0 0
Patient knowledge/education Prevention 5 0 0 3 3
Diabetes control and prevention Prevention 6 2 18 3 23
Cardiovascular Disease Complications 7 3 40 0 5
Patient safety Progression 7 5 64 2 4
Health Information Technology Progression 8 0 5 1 0
Patient Safety Prevention 9 24 29 0 3
Vitamin D Prevention 10 0 7 0 7
Classification Detection 11 4 0 0 ‡10
Obesity/Weight Management Prevention 12 0 0 5 1
Dietary strategies Progression 12 11 0 13 3
Inflammation Progression 12 2 21 0 5
Collaboration strategies Progression 12 0 0 2 1
Metabolic acidosis Progression 12 0 4 0 0
  1. * Topics with the same priority rank were tied in the overall score they received across all of the stakeholders. Rankings were based on responses received from 9 stakeholders.
  2. **Randomized controlled trial categories are not mutually exclusive.
  3. †Priority populations include: patients with diabetes, pediatric population, racial/ethnic minorities,
  4. and other vulnerable populations.
  5. ‡Ten observational studies examined priority populations (27 total). No randomized control trials.